What is Scanogen?
Scanogen is revolutionizing sepsis diagnosis with its innovative SMART technology, enabling rapid pathogen identification directly from whole blood. Their SMART-ID assay can detect pathogens responsible for 95% of bloodstream infections within two hours, a critical advancement for patient management and treatment outcomes. The S1 Instrument, designed for point-of-care settings, offers a fully automated system that enhances testing flexibility and efficiency. Scanogen's mission is to reduce sepsis-related mortality and morbidity, addressing the persistent challenges of slow diagnostic methods and the growing threat of antimicrobial resistance.
How much funding has Scanogen raised?
Scanogen has raised a total of $133K across 1 funding round:
Debt
$133K
Debt (2021): $133K with participation from PPP
Key Investors in Scanogen
PPP
Public-Private Partnership
What's next for Scanogen?
With substantial backing and a clear focus on late-stage development, Scanogen is poised to accelerate the commercialization and widespread adoption of its sepsis diagnostic solutions. The company's strategic investment will likely fuel further research and development, expand its market reach, and solidify its position as a leader in rapid pathogen identification. This funding will be instrumental in scaling operations to meet the growing demand for faster, more accurate diagnostic tools in critical care settings, ultimately aiming to improve global health outcomes.
See full Scanogen company page
